Lines of research
The field of Translational Genomics aims to enhance human health by leveraging the significant advancements made in genomic research and applying them to clinical practice. This endeavor involves developing prevention strategies; more effective therapeutic approaches; refining risk assessment through molecular characterization of diseases; and providing better decision-making tools for healthcare providers and patients. In the realm of musculoskeletal health, which serves as a model for other complex genetic diseases, our group envisions examining risk factors (biomarkers) across the lifespan. We aim to identify interventions that can prevent or delay the onset of conditions such as osteoporosis, sarcopenia, and frailty, with a focus on promoting healthy beginnings and sustainable paths to aging well.
Deep (musculo) skeletal phenotyping
Bone Mineral Density (BMD) assesses bone strength and fracture risk, crucial for diagnosing osteoporosis. Body composition evaluates lean and fat mass, impacting health. Trabecular Bone Score (TBS) and Bone Material Strength Index (BMSi) predict fracture risk. Sagittal alignment and Cobb’s angle assess spinal health. Muscle strength and jumping force evaluate physical function.
Translational genomics
Translational Genomics enhances human health by applying genetic research to clinical practice, improving therapies, refining risk assessments, and aiding decision-making. In musculoskeletal health, our group studies biomarkers to prevent or delay conditions like osteoporosis, sarcopenia, and frailty, promoting healthy aging and sustainable health trajectories.
